Creative Biolabs Launches Integrated Cell Therapy Platforms for Cancer Immunotherapy

Creative Biolabs announced the full integration of its one-stop-shop CAR-T and TIL therapy development platforms, offering researchers and biotech startups a seamless, end-to-end service for developing next-generation cellular immunotherapies. Recent regulatory approvals, including the FDA approval of lifileucel (Amtagvi) as the first tumor-infiltrating lymphocyte therapy for advanced melanoma, have demonstrated the therapeutic potential of cell-based therapies. Innovations in off-the-shelf CAR-NKT and armored CAR-T technologies continue to push the boundaries of what can be achieved with engineered immune cells.

The Smart™ CAR platform offers construction services for next-generation CAR designs, including novel constructs such as Dual CARs, TriCARs, Modular CAR, and Logic-gated CAR. The platform supports first- through fourth-generation CARs, along with armored variants that secrete immune modulators like IL-12. Each construct is tailored to the tumor biology and immune microenvironment for optimal efficacy and minimal toxicity. The CAR-T platform targeting solid tumors overcomes one of the most challenging obstacles in the discipline by employing bispecific CARs, checkpoint-resistant designs, and optimized delivery systems for improved infiltration and persistence.

Tumor-infiltrating lymphocyte therapy represents a breakthrough innovation in treating solid tumors. The one-stop TIL therapy development platform provides comprehensive and integrated services to meet the field's refined needs. TIL therapy is exceptionally well-positioned to identify heterogeneous neoantigens, and Creative Biolabs leads the way in TIL-based antibody discovery, utilizing patient-derived B cells to develop fully human antibodies with high specificity and therapeutic value. The company integrates cutting-edge technologies for facilitating accelerated and stable translation from bench to bedside, utilizing the latest in genetic and cellular engineering to ensure TILs are highly potent and specifically targeted against cancer cells. Researchers can learn more about these advanced platforms by visiting https://www.creative-biolabs.com/car-t/.